1. Home
  2. SKYT vs AUPH Comparison

SKYT vs AUPH Comparison

Compare SKYT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SkyWater Technology Inc.

SKYT

SkyWater Technology Inc.

HOLD

Current Price

$29.26

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$14.22

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKYT
AUPH
Founded
1991
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
SKYT
AUPH
Price
$29.26
$14.22
Analyst Decision
Buy
Buy
Analyst Count
5
4
Target Price
$26.50
$17.25
AVG Volume (30 Days)
3.2M
836.9K
Earning Date
02-25-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.62
0.55
Revenue
$346,587,000.00
$265,808,000.00
Revenue This Year
$28.48
$21.76
Revenue Next Year
$41.29
$16.45
P/E Ratio
$11.17
$25.87
Revenue Growth
0.19
20.62
52 Week Low
$5.67
$6.55
52 Week High
$36.27
$16.54

Technical Indicators

Market Signals
Indicator
SKYT
AUPH
Relative Strength Index (RSI) 50.51 38.73
Support Level $28.13 $14.21
Resistance Level $30.87 $14.66
Average True Range (ATR) 1.62 0.45
MACD -0.80 -0.02
Stochastic Oscillator 21.80 3.88

Price Performance

Historical Comparison
SKYT
AUPH

About SKYT SkyWater Technology Inc.

SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: